Bright Minds Biosciences Inc.
Performance History
| Key Stats | |
|---|---|
| Open | $1.39 |
| Prev. Close | $1.45 |
| EPS | -1.90 |
| Dividend | $0.00 |
| Next Earnings Date | May 15, 2023 |
| Dividend Yield % | - |
| Market Cap | $5.13M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 1.36 | 1.42 |
| 52 Week Range | 1.20 | 6.44 |
| Ratios | |
|---|---|
| P/B Ratio | 0.96 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | -$8.80M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -108.98% |
| EPS | -1.90 |
Score Breakdown
All Score (37 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| DRUG | Market | |
|---|---|---|
| Value | 62 | 42 |
| Quality | 39 | 46 |
| Ownership | 7 | 39 |
| Growth | 16 | 44 |
| Dividends | - | 32 |
All Score (37 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Bright Minds Biosciences Inc. (DRUG)
Bright Minds Biosciences Inc., a biotechnology company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Ian McDonald
- Headquarters
- New York
- Employees
- 0
Keep an eye on Bright Minds Biosciences Inc.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.